PL365480A1 - Cytotoksyczne immunokoniugaty przeciwciał specyficznych wobec CD44 - Google Patents
Cytotoksyczne immunokoniugaty przeciwciał specyficznych wobec CD44Info
- Publication number
- PL365480A1 PL365480A1 PL02365480A PL36548002A PL365480A1 PL 365480 A1 PL365480 A1 PL 365480A1 PL 02365480 A PL02365480 A PL 02365480A PL 36548002 A PL36548002 A PL 36548002A PL 365480 A1 PL365480 A1 PL 365480A1
- Authority
- PL
- Poland
- Prior art keywords
- cytotoxic
- antibody immunoconjugates
- immunoconjugates
- antibody
- Prior art date
Links
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112227A EP1258255A1 (en) | 2001-05-18 | 2001-05-18 | Conjugates of an antibody to CD44 and a maytansinoid |
| PCT/EP2002/005413 WO2002094325A2 (en) | 2001-05-18 | 2002-05-16 | Cytotoxic cd44 antibody immunoconjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL365480A1 true PL365480A1 (pl) | 2005-01-10 |
Family
ID=8177473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02365480A PL365480A1 (pl) | 2001-05-18 | 2002-05-16 | Cytotoksyczne immunokoniugaty przeciwciał specyficznych wobec CD44 |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP1258255A1 (pl) |
| JP (1) | JP2004529963A (pl) |
| KR (1) | KR20030097883A (pl) |
| CN (1) | CN1509187A (pl) |
| AR (1) | AR035977A1 (pl) |
| BG (1) | BG108366A (pl) |
| BR (1) | BR0209862A (pl) |
| CA (1) | CA2443438A1 (pl) |
| CO (1) | CO5550468A2 (pl) |
| CZ (1) | CZ20033477A3 (pl) |
| EA (1) | EA200301159A1 (pl) |
| EE (1) | EE200300568A (pl) |
| HR (1) | HRP20030932A2 (pl) |
| HU (1) | HUP0400046A3 (pl) |
| IL (1) | IL157965A0 (pl) |
| MX (1) | MXPA03010432A (pl) |
| NO (1) | NO20035108L (pl) |
| NZ (1) | NZ530167A (pl) |
| PE (1) | PE20021097A1 (pl) |
| PL (1) | PL365480A1 (pl) |
| SK (1) | SK15582003A3 (pl) |
| WO (1) | WO2002094325A2 (pl) |
| YU (1) | YU91503A (pl) |
| ZA (1) | ZA200307364B (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1417974A1 (en) * | 2002-11-08 | 2004-05-12 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy |
| DE10256083A1 (de) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| EP1651162B1 (en) * | 2003-05-20 | 2015-10-21 | ImmunoGen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| EA014640B1 (ru) * | 2003-07-21 | 2010-12-30 | Иммьюноджен, Инк. | Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения |
| CA2556027C (en) * | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| KR101281501B1 (ko) | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
| US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CN101374545B (zh) * | 2005-04-15 | 2012-03-28 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| AR059900A1 (es) * | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| JP5784592B2 (ja) | 2009-06-03 | 2015-09-24 | イミュノジェン・インコーポレーテッド | 抱合方法 |
| UY32913A (es) * | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| EA033468B1 (ru) | 2011-03-29 | 2019-10-31 | Immunogen Inc | Способы получения конъюгата "антитело-майтансиноид" |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| EP2904089A4 (en) | 2012-10-04 | 2016-05-25 | Immunogen Inc | USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES |
| GB201220899D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived pegylated peptides |
| GB201220889D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating metastasizing cancers |
| GB201220901D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| GB201220891D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating breast cancers |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| AU2014311361B2 (en) | 2013-08-26 | 2018-11-29 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| WO2016150521A1 (en) * | 2015-03-26 | 2016-09-29 | Fundación Imdea Nanociencia | Functionalised magnetic nanoparticle |
| CA2978340C (en) | 2015-03-27 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| MX390630B (es) | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| KR20230136699A (ko) | 2016-06-06 | 2023-09-26 | 노쓰웨스턴유니버시티 | 융합 단백질 작제물 |
| KR20210004961A (ko) * | 2018-02-22 | 2021-01-13 | 아브마트 상하이 컴퍼니, 엘티디. | 치료 항체 및 그의 용도 |
| CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
| DE19648209A1 (de) * | 1996-11-21 | 1998-05-28 | Boehringer Ingelheim Int | Verfahren zur Tumorzelldepletion CD34-positiver Zellen |
| DE19708713C2 (de) * | 1997-03-04 | 2002-11-28 | Boehringer Ingelheim Int | Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen |
| EP2977063A1 (en) * | 1999-06-25 | 2016-01-27 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| JP4776843B2 (ja) * | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法 |
-
2001
- 2001-05-18 EP EP01112227A patent/EP1258255A1/en not_active Withdrawn
-
2002
- 2002-05-16 IL IL15796502A patent/IL157965A0/xx unknown
- 2002-05-16 CZ CZ20033477A patent/CZ20033477A3/cs unknown
- 2002-05-16 KR KR10-2003-7015037A patent/KR20030097883A/ko not_active Withdrawn
- 2002-05-16 SK SK1558-2003A patent/SK15582003A3/sk not_active Application Discontinuation
- 2002-05-16 CN CNA028101634A patent/CN1509187A/zh active Pending
- 2002-05-16 HR HR20030932A patent/HRP20030932A2/xx not_active Application Discontinuation
- 2002-05-16 MX MXPA03010432A patent/MXPA03010432A/es not_active Application Discontinuation
- 2002-05-16 JP JP2002591041A patent/JP2004529963A/ja active Pending
- 2002-05-16 BR BR0209862-8A patent/BR0209862A/pt not_active IP Right Cessation
- 2002-05-16 EP EP02753054A patent/EP1395290A2/en not_active Withdrawn
- 2002-05-16 NZ NZ530167A patent/NZ530167A/en unknown
- 2002-05-16 EE EEP200300568A patent/EE200300568A/xx unknown
- 2002-05-16 YU YU91503A patent/YU91503A/sh unknown
- 2002-05-16 PL PL02365480A patent/PL365480A1/pl not_active Application Discontinuation
- 2002-05-16 WO PCT/EP2002/005413 patent/WO2002094325A2/en not_active Ceased
- 2002-05-16 EA EA200301159A patent/EA200301159A1/ru unknown
- 2002-05-16 CA CA002443438A patent/CA2443438A1/en not_active Abandoned
- 2002-05-16 HU HU0400046A patent/HUP0400046A3/hu unknown
- 2002-05-17 PE PE2002000420A patent/PE20021097A1/es not_active Application Discontinuation
- 2002-05-17 AR ARP020101829A patent/AR035977A1/es not_active Application Discontinuation
-
2003
- 2003-09-22 ZA ZA200307364A patent/ZA200307364B/en unknown
- 2003-11-17 NO NO20035108A patent/NO20035108L/no not_active Application Discontinuation
- 2003-11-17 BG BG108366A patent/BG108366A/bg unknown
- 2003-11-18 CO CO03101695A patent/CO5550468A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094325A3 (en) | 2003-04-17 |
| HUP0400046A3 (en) | 2006-02-28 |
| WO2002094325A2 (en) | 2002-11-28 |
| NO20035108D0 (no) | 2003-11-17 |
| EP1258255A1 (en) | 2002-11-20 |
| EP1395290A2 (en) | 2004-03-10 |
| EE200300568A (et) | 2004-04-15 |
| NO20035108L (no) | 2003-11-17 |
| CN1509187A (zh) | 2004-06-30 |
| CA2443438A1 (en) | 2002-11-28 |
| AR035977A1 (es) | 2004-07-28 |
| CO5550468A2 (es) | 2005-08-31 |
| MXPA03010432A (es) | 2004-04-02 |
| HRP20030932A2 (en) | 2004-04-30 |
| SK15582003A3 (sk) | 2004-04-06 |
| CZ20033477A3 (en) | 2004-05-12 |
| NZ530167A (en) | 2005-10-28 |
| IL157965A0 (en) | 2004-03-28 |
| BG108366A (bg) | 2004-09-30 |
| ZA200307364B (en) | 2004-04-20 |
| YU91503A (sh) | 2006-05-25 |
| BR0209862A (pt) | 2004-06-08 |
| EA200301159A1 (ru) | 2004-06-24 |
| PE20021097A1 (es) | 2003-02-13 |
| HUP0400046A2 (hu) | 2004-04-28 |
| JP2004529963A (ja) | 2004-09-30 |
| KR20030097883A (ko) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL157965A0 (en) | Cytotoxic cd44 antibody immunoconjugates | |
| HUP0400466A3 (en) | G-csf conjugates | |
| ZA200400521B (en) | Antibodies to OPGL. | |
| MXPA03009390A (es) | Anticuerpos para integrina vla-1. | |
| SI2371392T1 (sl) | Konjugati derivat-nosilec kaliheamicina | |
| HUP0203751A3 (en) | G-csf conjugates | |
| ZA200003998B (en) | Pharmaceutical compositions. | |
| EP1443963A4 (en) | ANTIBODY TARGETING COMPOUNDS | |
| GB0009887D0 (en) | Cytotoxic agents | |
| GB0124523D0 (en) | Pharmaceutical combination | |
| PL370669A1 (pl) | Kompozycja farmaceutyczna | |
| MXPA03002105A (es) | Composiciones farmaceuticas. | |
| GB0119665D0 (en) | Conjugates | |
| EP1379689A4 (en) | OLIGONUCLEOTIDE CONJUGATES | |
| GB0129397D0 (en) | Pharmaceutical combination | |
| ZA200110500B (en) | Pharmaceutical composition. | |
| GB0129395D0 (en) | Pharmaceutical combination | |
| MXPA03007318A (es) | Composicion farmaceutica. | |
| ZA200110501B (en) | Pharmaceutical composition. | |
| GB0224767D0 (en) | Hemoglobin conjugates | |
| ZA200110499B (en) | Pharmaceutical composition. | |
| GB0122196D0 (en) | Improvements to the n-plex transceiver | |
| GB0122410D0 (en) | Cancer diagnosis | |
| GB0119004D0 (en) | Antibody | |
| ZA200204623B (en) | G-CSF conjugates. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |